CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.
May 20th 2022
NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.
May 18th 2022
Dying does not have the be scary, and there are resources available to help patients and their loved ones, explained an expert.
May 11th 2022
The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.
April 15th 2022
The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.
April 6th 2022
The COVID-19 pandemic brought on a huge surge in the use of telemedicine for cancer care, but now as the pandemic is slowing down, an expert said that there are certain times when telemedicine will do, while other situations warrant an in-person visit with the doctor.
March 14th 2022
Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.
March 2nd 2022
CAR-T cell therapies offer patients with lymphoma a chance for long-term remission, but none have yet to receive a greenlight from the FDA as a first line of treatment.
March 2nd 2022
Treatment with ofatumumab plus an aggressive regimen of chemotherapies resulted in a response rate of more than 80% in patients with newly diagnosed mantle cell lymphoma.
February 25th 2022
Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.
February 16th 2022
In the midst of my treatment for mantle cell lymphoma, I had to suffer through the feeling of wanting to crawl out of my own skin when my oncologist gave me a medication tapering plan that was not gradual enough.
February 14th 2022
From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.
February 14th 2022
Supportive care should be implemented promptly after patients receive CAR-T cell therapy, but as one expert notes, patients with cancer are often referred for this care too late.
February 9th 2022
A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.
January 11th 2022
The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.
December 23rd 2021
New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.
November 19th 2021
With three BTK inhibitors approved for treatment of mantle cell lymphoma, patients and providers should consider side effects and insurance coverage before deciding on a drug.
November 1st 2021
The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.
October 18th 2021
More selective BTK inhibitors like Brukinsa may give patients with mantle cell lymphoma who progressed on prior therapies another option with potentially fewer and more manageable side effects.
September 17th 2021
After determining an aggressive or non-aggressive treatment approach to mantle cell lymphoma, patients and clinicians must then discuss COVID-19 vaccine efficacy when determining a maintenance treatment strategy.
September 15th 2021
Tecartus was the first CAR-T cell therapy to be approved for the treatment of recurrent mantle cell lymphoma. Now, more than a year after its approval, a doctor discusses his experience prescribing the drug.
August 19th 2021
Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.
August 4th 2021
Some patients with mantle cell lymphoma can opt for a wait-and-watch approach, while others will need more aggressive treatment.
July 26th 2021
About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.
July 16th 2021
When patients with mantle cell lymphoma are discussing the use of a BTK inhibitor, they must consider what their insurance will cover, as well as current health complications and potential side effects.
July 14th 2021
Patients can now prioritize whether durable responses to treatment or avoiding certain side effects are more valuable to them.
July 13th 2021
Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.
July 2nd 2021
The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.
June 29th 2021
Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.
May 28th 2021
Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.